Mutations in mtDNA are responsible for a variety of mitochondrial diseases, where the mitochondrial tRNA Leu(UUR) gene has especially hot spots for pathogenic mutations. Clinical features often depend on the tRNA species and͞or positions of the mutations; however, molecular pathogenesis elucidating the relation between the location of the mutations and their leading phenotype are not fully understood. We report here that mitochondrial tRNAs Leu(UUR) harboring one of five mutations found in tissues from patients with symptoms of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) (A3243G, G3244A, T3258C, T3271C, and T3291C) lacked the normal taurine-containing modification (5-taurinomethyluridine) at the anticodon wobble position. In contrast, mitochondrial tRNAs Leu(UUR) with different mutations found in patients that have mitochondrial diseases but do not show the MELAS symptoms (G3242A, T3250C, C3254T, and A3280G) had the normal 5-taurinomethyluridine modifications. These observations were made by using a modified primer extension technique that can detect the modification deficiency in the extremely limited quantities of mutant tRNAs obtainable from patient tissues. These results strongly suggest deficient wobble modification could be a key molecular factor responsible for the phenotypic features of MELAS, which can explain why the different MELAS-associated mutations result in indistinguishable clinical features.
Mutations in mtDNA are responsible for a variety of mitochondrial diseases, where the mitochondrial tRNA Leu(UUR) gene has especially hot spots for pathogenic mutations. Clinical features often depend on the tRNA species and͞or positions of the mutations; however, molecular pathogenesis elucidating the relation between the location of the mutations and their leading phenotype are not fully understood. We report here that mitochondrial tRNAs Leu(UUR) harboring one of five mutations found in tissues from patients with symptoms of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) (A3243G, G3244A, T3258C, T3271C, and T3291C) lacked the normal taurine-containing modification (5-taurinomethyluridine) at the anticodon wobble position. In contrast, mitochondrial tRNAs Leu(UUR) with different mutations found in patients that have mitochondrial diseases but do not show the MELAS symptoms (G3242A, T3250C, C3254T, and A3280G) had the normal 5-taurinomethyluridine modifications. These observations were made by using a modified primer extension technique that can detect the modification deficiency in the extremely limited quantities of mutant tRNAs obtainable from patient tissues. These results strongly suggest deficient wobble modification could be a key molecular factor responsible for the phenotypic features of MELAS, which can explain why the different MELAS-associated mutations result in indistinguishable clinical features.
mitochondrial tRNA ͉ taurine modification M utations in mtDNA are associated with a wide spectrum of human diseases that are caused by mitochondrial dysfunction. In particular, point mutations in mitochondrial tRNA genes are frequently found in mitochondrial diseases (1) . Although Ͼ90 different mutations within mitochondrial tRNA genes are currently listed as being pathogenic (MITOMAP: A Human Mitochondrial Genome Database, www.mitomap.org) (2), the molecular pathogenesis behind the mitochondrial dysfunction induced by these mutations and the relationship between the genotype and the clinical phenotype are not fully understood.
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), one of the major clinical subgroups of the mitochondrial encephalomyopathies, is caused by single base replacements in the mitochondrial tRNA Leu responsible for the UUR (R ϭ A or G) leucine codons [tRNA Leu(UUR) ]. In fact, the mitochondrial tRNA Leu(UUR) gene is a hot spot for pathogenic mutations that are associated with mitochondrial diseases with various clinical features because 21 different point mutations in the mitochondrial tRNA Leu(UUR) gene have been reported (MITOMAP, www.mitomap.org) (2) . Most patients with pathogenic mutations in this gene show symptoms of MELAS, although some do express clinical features other than MELAS, including cardiomyopathy, myopathy, a combination of myopathy and cardiomyopathy, and more complex syndromes characterized by progressive external ophthalmoplegia and variable degrees of encephalopathy. In particular, the A3243G or T3271C mutation in the mitochondrial tRNA Leu(UUR) gene has been observed in the majority of MELAS patients (3) (4) (5) . The symptoms caused by the two different mutation positions are clinically indistinguishable except for the age when the first episodic attack occurs (6) . In addition, the G3244A (M. Mimaki, T. Ichiyama, H. Isumi, S. Furukawa, M. Akasaka, Y. Fujii. J. Kamei, H. Komaki, I. Nonaka, and Y.G., unpublished work), T3258C (7) or T3291C (8) mutations in the mitochondrial tRNA Leu(UUR) gene have been reported as being pathogenic in some MELAS patients.
The construction of cybrid cell lines, in which mutant mtDNA derived from patients is intercellularly transferred into human cells lacking mtDNA ( 0 cells), has demonstrated the direct involvement in mitochondrial dysfunction of pathogenic mutations in mtDNA (9, 10) . In this way, the A3243G and T3271C point mutations were shown to decrease mitochondrial respiratory activity without nuclear gene involvement (11, 12) . Several additional lines of studies have proposed that the MELAS mutations in the mitochondrial tRNA Leu(UUR) molecule directly impair termination of transcription (13) , decrease RNase P processing (14) , tRNA stability, and aminoacylation (15) , and induce an abnormal tRNA conformation (16) that together lead to a decreased steady-state level of the normal aminoacylated tRNA, which in turn reduces mitochondrial protein synthesis. However, the reduced mitochondrial protein synthesis in cells with these pathogenic mutations cannot explain why these cells also show decreased respiratory activity or oxygen consumption because the protein synthesis level does not seem to parallel the enzymatic activity involved in these processes (11, 12, 14, 17) . Thus, the reduced protein synthesis caused by the quantitative reduction in mutant tRNA levels does not appear to be the direct cause of the clinical symptoms of MELAS.
We have previously shown that in cybrid cells possessing homoplasmic pathogenic mutations, the taurine-containing modified uridine (5-taurinomethyluridine, m 5 U) (18) that is normally found at the anticodon wobble position of mitochondrial tRNA Leu(UUR) remains unmodified in mitochondrial tRNA Leu(UUR) molecules bearing the MELAS A3243G or T3271C mutation (19) . In addition, we have shown that the mitochondrial tRNA Lys with the A8344G mutation, which is found in most myoclonus epilepsy associated with ragged-red fibers patients (20) , another major subgroup of the mitochondrial encephalomyopathies, also lacks a normal taurine modification (5-taurinomethyl-2-thiouridine) at the wobble position (18, 21) . These two types of mitochondrial diseases thus have in common the lack of taurine modification of their respective mutant tRNAs. Thus, these point mutations may hinder the biosynthesis of the wobble taurine modification of mitochondrial tRNAs. It is known that uridine modifications at the wobble position are required for precise and efficient codon recognition (22) (23) (24) . Recently, we reported that mitochondrial tRNAs Leu(UUR) lacking the taurine modification showed severely reduced UUG translation but no decrease in UUA translation (25) . We thus concluded that the UUG codon-specific translational defect of the mutant mitochondrial tRNAs Leu(UUR) could play an important role in the molecular pathogenesis of MELAS. This finding could explain the translational defect of UUG-rich genes such as ND6 that leads to the complex I deficiency observed clinically in MELAS patients.
To investigate the relationship between the clinical features of MELAS and taurine modification deficiency, we wanted to analyze the modification deficiency in actual tissues from patients with various mutations in the mitochondrial tRNA Leu(UUR) gene. However, because of the extremely limited amounts of mitochondrial tRNAs available from patient tissues, this objective required the development of a technique that would detect with high sensitivity the modification deficiency. We thus devised a technique based on primer extension and here describe that the mutant mitochondrial tRNAs Leu(UUR) obtained from MELAS patient tissues bear the wobble modification deficiency, unlike the mutant mitochondrial tRNAs Leu(UUR) obtained from patients with other diseases. This finding clearly reveals the specific correlation between the wobble modification deficiency and the clinical features of MELAS. This finding will aid the development of appropriate therapeutic measures and diagnostic applications.
Methods

Patient Tissues and Cell
Lines. Approximately 0.5 g of liver and cardiac muscle was obtained from the A3243G MELAS patient (3). The other tissues used were frozen sections of patient skeletal muscles (1-10 mg) (5, 7, 8, 26) . The mutant cybrid cell lines that had been constructed by the intercellular transfer of MELAS patient mtDNA into 0 HeLa cells have been described (19) . The ML2-2-2 and ML5-1-13 cell lines exclusively contain mtDNA with the A3243G and T3271C point mutations, respectively. The cells were cultured in normal medium [DMEM͞F-12 (1:1) (GIBCO͞BRL), 10% FCS].
Primer Extension Method to Detect the Taurine Modification of
Wobble Uridines. Crude RNAs from frozen tissue sections or cybrid cells were obtained by using Isogen (Nippon Gene, Tokyo) according to the manufacturer's instructions. The 5Ј 32 P-labeled primer (0.1 pmol) was incubated with 0.1-0.5 g of the total RNAs in a 10-l solution containing 10 mM Tris⅐HCl (pH 8.0), 1 mM EDTA at 80°C for 2 min and then allowed to stand at room temperature for 1 h. Subsequently, 1.5 l of ddH 2 O, 4 l of 5ϫ reaction buffer for reverse transcription (Toyobo, Osaka), 0.5 l of d͞ddNTP mix containing 1.5 mM Modification deficiency values were calculated on the basis of the intensities of the upper and lower bands. The ratio of the upper band intensity for WT tRNA was subtracted from the band intensity ratio for each mutant tRNA as a background. The calculated data were normalized on the basis of the A3243G cybrid data, which were set at 100. Each data set represents the average of three independent experiments, with bars showing the SD. The percentage of input A3243G mutant tRNA Leu(UUR) relative to total tRNA Leu(UUR) in each sample was determined by a conventional primer extension method (see Fig. 5 ).
each of dATP, dTTP, and ddGTP (ultrapure products, Amersham Pharmacia), 3 l of 25 mM MgCl 2 , and 1 l of Moloney murine leukemia virus reverse transcriptase (RNase H Ϫ ) (40 units͞l, Toyobo) were added, and the mixture was incubated at 42°C for 1 h. The reaction mixture was subjected to 15% PAGE containing 7 M urea (40 cm). The radiolabeled bands were visualized by a BAS5000 bioimaging analyzer (Fuji). The synthetic DNA primers used were as follows: 5Ј-ACCTCTGACT-GTAAGG-3Ј for 3271 mutant tRNA Leu(UUR) , 5Ј-ACCTC-CGACTGTAAAG-3Ј for 3280 mutant tRNA Leu(UUR) , and 5Ј-ACCTCTGACTGTAAAG-3Ј for other mutant tRNAs Leu(UUR) . For the primer extension method with unlabeled primer and [␣-32 P]dATP (Fig. 1b) , 0.1 pmol of unlabeled primer, 0.25 M [␣-32 P]dATP, 0.15 mM dATP, and 1.5 mM each of dTTP and ddGTP were used.
Results
It was previously not possible to analyze the mitochondrial tRNA modifications in patients by conventional techniques as that would require the isolation of sufficient amounts of mutant mitochondrial tRNAs directly from the patient tissues, which is not practicable given the limited amounts of patient tissues or biopsy specimens that are available. Furthermore, as the patient tissues often bear heteroplasmic point mutations in their mtDNA, the amounts of the mutant tRNA that can be isolated depends on the frequency with which the mutation occurs and the stability of the mutant tRNA in the mitochondria. To overcome these difficulties, we have established a sensitive method for detecting the wobble modification deficiency in mutant mitochondrial tRNA Leu(UUR) molecules. This method was developed by optimizing a primer extension technique (Fig.  1a) with the 5Ј-32 P phosphorylated DNA primer that is complementary to positions 39-54 of mitochondrial tRNA Leu(UUR) and that specifically hybridizes to mitochondrial tRNA Leu(UUR) in the total RNAs obtained from cybrid cells or patient tissues. After hybridization, reverse transcription of the tRNA from the primer is then carried out in the presence of dideoxy GTP. When total RNA from WT cells was used as the template in this experiment, the m 5 U34 modification in mitochondrial tRNA Leu(UUR) hinders the extension by acting as a roadblock. As a result, a specific band ending at U33 is observed, as shown by the lower band in Fig. 1a . However, when total RNA from A3243G cybrid cells was used, the extension continued through the unmodified U34 residue and stopped at C32 because of the insertion of dideoxy guanosine (Fig. 1a, upper band) . We confirmed that the reverse transcription on mitochondrial tRNA Leu(UUR) was correctly performed by dideoxy sequencing reactions using in vitro-transcribed mitochondrial tRNA Leu(UUR) as a template (Fig. 1a) . In addition, the same experiment was performed with unlabeled primer and [␣-32 P]dATP to confirm that the extension terminated at U33 when the template tRNA contains m 5 U (Fig. 1b) . By adjusting the total RNAs from patient and WT tissues that contain the same amount of mitochondrial tRNA Leu(UUR) , the radioactivity of the lower band ending at U33 of WT tRNA was almost the same as that of the upper band ending at C32 of A3243G mutant tRNA (Fig. 1b) , which suggests that m 5 U hindered the reverse transcription by incorporating two dAMPs at m 5 U34 and U33. Furthermore, we performed this experiment with total RNAs composed of various ratios of the mutant mitochondrial tRNA Leu(UUR) with A3243G mutation relative to the WT tRNA (Fig. 1c) . The upper and lower band intensities were quantified, and the ratios were calculated to yield values of modification deficiency that were almost proportional to the ratio of input A3243G mutant mitochondrial tRNA Leu(UUR) (Fig. 1c) . Thus, this method allows us to detect the modification deficiency by measuring the ratio of the intensities of the upper and lower bands. Most importantly, we can analyze the wobble modification deficiency of the mutant mitochondrial tRNA Leu(UUR) in as little as 0.5 g of the total RNA that was isolated from Ϸ0.1-1 mg of frozen muscle sections or other tissues obtained from the patients.
In the case of mutant mitochondrial tRNA Leu(UUR) with the T3271C mutation, because the mutation is located within the sequence that hybridizes to the primer, the oligo primer complementary to the T3271C mutant mitochondrial tRNA Leu(UUR) specifically discriminates the mutant tRNA from the WT tRNA, thus detecting the modification deficiency of the mutant tRNA with even higher sensitivity than it detects the deficiency in A3243G mutant mitochondrial tRNA Leu(UUR) (Fig. 2) . In fact, we can detect the modification deficiency in substantially lower amounts of the T3271C mutant tRNA (4%) (Fig. 2) . The sensitivity of this technique permitted us to use it to assess the modification deficiency in all T3271C MELAS patients. In contrast, because this method is less sensitive with regard to A3243G mutant tRNA (Fig. 1c) , it cannot detect the modification deficiency of the mutant tRNAs if the mutation frequency of the mitochondrial tRNA is Ͻ20%.
To analyze the wobble modification deficiency in patient tissues by the modified primer extension technique, we chose tissues from five MELAS, two mitochondrial myopathies, one chronic progressive external ophthalmoplegia and one maternally inherited mytochondrial myopathy and cardiomyopathy patient that bear various point mutations in their mitochondrial tRNA Leu(UUR) gene along with a substantial mutation rate in their mtDNA (Ͼ50%) ( Table 1) . Because the patient tissues bear heteroplasmic point mutations in their mtDNA, we first measured the mutation frequency of the mitochondrial tRNA Leu(UUR) from the patient tissues and cybrid cells by using a conventional primer extension method (Fig. 5 , which is published as supporting information on the PNAS web site). This method is used because the mutation frequencies of the heteroplasmic mtDNAs do not always correspond to that of mitochondrial tRNAs caused by the possible reduction of tRNA stability resulting from the pathogenic mutation.
The liver and cardiac muscle samples with the A3243G mutation that we used originated from the same MELAS patient. Analysis of the tissues from MELAS patients with the Fig. 2 . The primer extension method using a discriminating primer detects the taurine modification deficiency in T3271C mutant mitochondrial tRNA Leu(UUR) with particularly high sensitivity. The wobble taurine modification deficiency in T3271C mutant mitochondrial tRNA Leu(UUR) was detected by the primer extension method by using a discriminating primer that contains guanine in its 3Ј region for specifically analyzing T3271C mitochondrial mutant tRNA Leu(UUR) . The C on a round black background in the anticodon stem indicates the T-to-C point mutation at np 3271. The primer is shown as a solid line next to the anticodon region of the tRNAs, and the nascent cDNAs synthesized from the primer are indicated as gray lines. The percentage of mutant tRNA in each sample was determined by the primer extension method (Fig. 5) .
A3243G or T3271C mutation with our primer extension technique revealed the marked presence of the upper band that indicates the lack of modification (Fig. 3a) . Modification deficiency values are shown in Fig. 3c . These results are consistent with our previous observations found in the mutant tRNAs from the cybrid cells (19) . Lower modification deficiency values were observed for the A3243G (liver), A3243G (cardiac muscle), and T3271C (skeletal muscle) tissues. This finding can be explained by the low mutation frequency of the heteroplasmic mtDNAs in these tissues, which generated the mutant tRNAs at a ratio of only 57%, 70%, and 85%, respectively ( Fig. 3 and Table 1 ). In addition, we found the wobble modification deficiency in three other mutant mitochondrial tRNAs Leu(UUR) from MELAS patients, namely, G3244A (M. Mimaki, T. Ichiyama, H. Isumi, S. Furukawa, M. Akasaka, Y. Fujii. J. Kamei, H. Komaki, I. Nonaka, and Y.G., unpublished work), T3258C (7), and T3291C (8) (Fig. 3 b and c) . That the G3244A and T3291C tissues showed respective modification deficiency rates of only 64% and 30% despite the mutant tRNAs being present at 87% and 62% of the total tRNAs Leu(UUR) , respectively, suggests that the mutant tRNAs with these point mutations only partially lack the wobble modification. In contrast, the G3242A (M. Mimaki, T. Ichiyama, H. Isumi, S. Furukawa, M. Akasaka, Y. Fujii. J. Kamei, H. Komaki, I. Nonaka, and Y.G., unpublished work), T3250C (26) , and C3254T and A3280G (7) tissues from the four patients with other mitochondrial myopathies or chronic progressive external ophthalmoplegia showed normal levels of the wobble modification ( Fig. 3 b and c) . These results strongly suggest an apparent link between the wobble modification deficiency and the phenotypic features of MELAS (Fig. 4 and Table 1 ).
Discussion
In this study, we describe an application of primer extension method to detect the wobble taurine modification (m 5 U) in mitochondrial tRNA Leu(UUR) . Primer extension analysis has been used previously to detect a variety of RNA modifications (27) . One of its applications was to map 2Ј-O-methylated ribose in ribosomal RNA (28) . In such cases, the primer extension reaction is performed with low dNTP concentrations, and the modified nucleotides in the template ribosomal RNA interfere with the normal passage of reverse transcriptase, thus resulting in transcription arrest at the nucleotide preceding the site of modification. Modified nucleosides that are unable to form a canonical Watson-Crick base pair such as 1-methyladenosine, wybutosine, or other modifications can be easily detected with this method because they block the reverse transcription reaction, thereby yielding a specific band that ends at the base preceding the modified residue. In our technique, however, the reverse transcription normally proceeds through the m 5 U34 modification and stops at the base next to m 5 U (U33). In contrast, when the m 5 U34 modification is absent, the transcription stops at C32. The molecular mechanism by which the m 5 U34 modification hinders reverse transcription differs from that used by the general method described above, because the modification at the C5 position of uridine does not block the Watson-Crick base pairing in the nascent cDNA resulting from the reverse transcription.
By using this detection system, we succeeded in identifying the wobble modification deficiency of mutant mitochondrial tRNAs Leu(UUR) in extremely limited amounts of the total RNA (0.5 g) obtained from patient tissues (Ϸ0.1-1 mg) . This experiment revealed that the mitochondrial tRNAs Leu(UUR) with five different point mutations (A3243G, G3244A, T3258C, T3271C, and T3291C) derived from patients showing the clinical features of MELAS lack the taurine modification (although G3244A and T3291C mutants may only partially lack the modification) ( Table  1 and Fig. 4 Right). Thus, each of these point mutations acts as a negative determinant for m 5 U biosynthesis. In contrast, the mitochondrial tRNAs Leu(UUR) with four different mutations (G3242A, T3250C, C3254T, and A3280G) from patients showing non-MELAS symptoms retained normal taurine modifications (Table 1 and Fig. 4 Left). These results clearly indicate the strong association between deficient taurine modification and the clinical features of MELAS.
Many studies have shown defective aspects of MELAS mutant mitochondrial tRNA Leu(UUR) other than the wobble modification, including decreased aminoacylation and stability, impaired pre-tRNA processing, and abnormal conformation (29, 30) . These dysfunctions commonly lead to the quantitative decrease of the aminoacylated mitochondrial tRNA Leu(UUR) , which in turn leads to the decreased translation of both UUA and UUG codons. Meanwhile, the most remarkable observation in this study is that all five different point mutations associated with MELAS showed the lack of the wobble modification in the mitochondrial tRNAs Leu(UUR) harvested from the tissues of patients with these mutations. This finding strongly suggests deficient wobble modification could be a key molecular factor responsible for the phenotypic features of MELAS, although the mitochondrial dysfunction in MELAS could arise from multiple causes. We have already demonstrated the characteristic translational disorder caused by wobble modification deficiency of MELAS mutant mitochondrial tRNA Leu(UUR) (25) . Mitochondrial tRNA Leu(UUR) that does not bear a pathogenic mutation but lacks the taurine modification, which was constructed from native WT human mitochondrial tRNA Leu(UUR) by a molecular surgery technique, showed a UUG codon-specific decoding disorder. Thus, the taurine modification at the C5 position of wobble uridine in mitochondrial tRNA Leu(UUR) appears to play a crucial role in the decoding of the UUG codon by stabilizing the U:G wobble base pairing. This result could nicely explain the translational defect of the respiratory complex I component ND6, whose gene is rich in UUG, that was observed in the MELAS cybrid cells (12, 17) . Because complex I deficiency is a typical phenotype of MELAS symptom (31, 32) , it appears the wobble modification deficiency of the mutant mitochondrial tRNA Leu(UUR) molecule is a major molecular contributor to MELAS pathogenesis. In addition, we estimated the negative effect on decoding the cognate UUA codon the pathogenic point mutation has by itself, independent of the wobble modification deficiency (25) . The MELAS mitochondrial tRNA Leu(UUR) with the A3243G mutation showed a more severe reduction in UUA decoding than the mitochondrial tRNA Leu(UUR) with the T3271C mutation. This result is consistent with the translational activities of MELAS cybrid cells with these point mutations (11, 12) . The negative effect of these pathogenic point mutations may arise from the fragile relaxed structure caused by the mutations, because A3243G could disrupt the potential tertiary interaction in the tRNA (33) (34) (35) , whereas the T3271C mutation destabilizes the anticodon stem (36) . Therefore, it is assumed that each of the three other MELAS mutations (G3244A, T3258C, and T3291C) results in a similar decoding disorder, albeit perhaps to different extents. The level of the translational defect imposed by each mutation may be determined by a combination of the pathogenic nature of each MELAS mutation and the wobble modification deficiency. In the case of the four other mutations (G3242A, T3250C, C3254T, and A3280G) found in patients with mitochondrial diseases showing non-MELAS symptoms, because the mitochondrial tRNAs Leu(UUR) with each of these mutations had the normal m 5 U modification, it appears that these mutations are directly responsible for tRNA disorders that lead to mitochondrial dysfunction, although it remains a possibility that these mutations may induce deficiencies in other tRNA modifications. Leu(UUR) . Each data set represents the average of three independent experiments, with bars showing the SD. The percentage of each mutant mitochondrial tRNA Leu(UUR) relative to total mitochondrial tRNA Leu(UUR) in each sample as determined by the primer extension method (Fig. 5) is shown in parentheses. 3243(L) and 3243(C), respectively, indicate the liver and cardiac muscle of the A3243G MELAS patient (see Table 1 ). To date, we have found five MELAS and one myoclonus epilepsy associated with ragged-red fibers mutation to be associated with the wobble modification deficiency. This finding suggests that the deficiencies in RNA modifications may be frequently caused by the pathogenic point mutations in mitochondrial tRNAs. The direct destruction of tRNA function by a point mutation would be best obtained by introducing a mutation into any of the anticodon bases or discriminator bases that are critical for codon recognition and aminoacylation. However, of the 90 pathogenic point mutations in mitochondrial tRNA genes that have been reported to be associated with mitochondrial diseases (MITOMAP, www.mitomap.org) (2) , only a few occur at such critical positions. This finding indicates that pathogenic mutations of this nature result in a severe phenotype that is incompatible with embryogenesis and development. In contrast, pathogenic mutations that result in only a mild phenotype or cause an RNA modification deficiency may not hamper development and only manifest themselves later as mitochondrial diseases. Supporting this idea is that it is known that most RNA modifications are nonessential and work to modulate or finetune RNA functions.
Our observations have provided an understanding of the molecular pathogenesis behind the human mitochondrial diseases arising from RNA modification disorders, although how impaired mitochondrial translation leads to the development of pathogenic cells and tissues to cause the observed biochemical defect remains to be elucidated. In retrospect, it is not surprising that a qualitative disorder of RNA molecules can cause disease because noncoding RNAs are functional molecules that must mature by undergoing posttranscriptional modifications. The primer extension method for detecting the modification deficiency can be used to detect other modifications in the limited quantities of RNAs obtainable from patient tissues.
